ArticleCureus2024
Conjunctival Advancement Procedure for Repairing Conjunctival Exposure of the PreserFlo MicroShunt.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Tube perforation after bleb reformation after PreserFlo MicroShunt implantation.Frontiers in ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 59-year-old Japanese woman with primary open-angle glaucoma underwent PreserFlo MicroShunt (PFM) (Santen Pharmaceutical Co., Ltd., Osaka, Japan) implantation in her left eye. Six weeks postoperatively, a conjunctival exposure of the posterior end of the device was observed, accompanied by aqueous leakage. The patient had no identifiable risk factors for exposure, such as previous conjunctival incisional surgeries, significant blepharitis, or needling procedures. Conjunctival advancement surgery was performed to cover the exposed device. After the sufficient dissection of scar tissue surrounding the PFM and the reapproximation of the conjunctiva, the device was successfully covered. Postoperatively, the filtration bleb remained formed, and the intraocular pressure (IOP) was controlled. No recurrence of device exposure was observed after 18 months of follow-up. Although PFM device exposure is a rare complication, it requires prompt surgical intervention to prevent infection and maintain IOP control. Conjunctival advancement surgery is an effective treatment option that allows for the repair of the exposure while preserving the filtration function of the device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.